Artemis Investment Management Llp Increased Axogen Inc (NASDAQ:AXGN) Stake by $14.51 Million

August 12, 2018 - By Jacob Reddy

AxoGen, Inc. (NASDAQ:AXGN) Logo

Artemis Investment Management Llp increased its stake in Axogen Inc (NASDAQ:AXGN) by 153.67% based on its latest 2018Q2 regulatory filing with the SEC. Artemis Investment Management Llp bought 290,254 shares as the company’s stock rose 53.73% while stock markets declined. The institutional investor held 479,136 shares of the health care company at the end of 2018Q2, valued at $24.07M, up from 188,882 at the end of the previous reported quarter. Artemis Investment Management Llp who had been investing in Axogen Inc for a number of months, seems to be bullish on the $1.47 billion market cap company. The stock decreased 2.41% or $0.95 during the last trading session, reaching $38.45. About 286,386 shares traded. AxoGen, Inc. (NASDAQ:AXGN) has risen 194.48% since August 13, 2017 and is uptrending. It has outperformed by 181.91% the S&P500.

Artemis Investment Management Llp, which manages about $7.33B US Long portfolio, decreased its stake in Comerica Inc (NYSE:CMA) by 215,970 shares to 808,634 shares, valued at $73.53M in 2018Q2, according to the filing. It also reduced its holding in Mondelez Intl Inc (NASDAQ:MDLZ) by 247,600 shares in the quarter, leaving it with 416,000 shares, and cut its stake in Oracle Corp (NYSE:ORCL).

AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage

Among 4 analysts covering AxoGen (NASDAQ:AXGN), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AxoGen had 6 analyst reports since March 1, 2018 according to SRatingsIntel. The firm earned “Overweight” rating on Tuesday, May 1 by Cantor Fitzgerald. Lake Street maintained the stock with “Buy” rating in Friday, March 2 report. The rating was maintained by JMP Securities on Tuesday, May 1 with “Market Outperform”. Cantor Fitzgerald maintained AxoGen, Inc. (NASDAQ:AXGN) on Wednesday, February 28 with “Buy” rating. The firm has “Market Outperform” rating by JMP Securities given on Thursday, March 1. The firm has “Buy” rating by Leerink Swann given on Tuesday, June 26.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company has market cap of $1.47 billion. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It currently has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

More important recent AxoGen, Inc. (NASDAQ:AXGN) news were published by: which released: “AxoGen, Inc. to Present at Canaccord Genuity Growth Conference” on July 25, 2018, also published article titled: “AxoGen, Inc. Reports 2018 Second Quarter Financial Results”, published: “5 Incredible Stocks to Buy Now That Wall Street Ignores” on August 09, 2018. More interesting news about AxoGen, Inc. (NASDAQ:AXGN) was released by: and their article: “Here’s Why AxoGen, Inc. Fell as Much as 18.6% Today” with publication date: August 02, 2018.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.